에를로티닙과 라파티닙을 사용한 환자에서 발생한 표층점상각막병증 = Superficial Punctate Keratoepitheliopathy Under Treatment with Erlotinib and Lapatinib

다국어 초록 (Multilingual Abstract)

Purpose: To report the corneal superficial punctate keratoepitheliopathy in 2 patients taking the epidermal growth factor receptor (EGFR) inhibitors, erlotinib and lapatinib, respectively. Case summary: Case 1, who received erlotinib, showed trichomegaly without touching the cornea and diffuse punctate keratoepitheliopathy. Corneal epitheliopathy and the corresponding symptoms resolved after discontinuation of the drug then recurred with reapplication. Case 2 presented diffuse corneal punctate epithelial erosions that developed without any cilia involvement after the patient was administered lapatinib. The visual acuity of both patients was not severely diminished and keratoepitheliopathy was mostly resolved with the treatment of preservative-free artificial tears and autologous serum eye drops. Conclusions: Erlotinib and lapatinib are both likely to cause visually tolerable corneal punctate keratoepitheliopathy which can be resolved with appropriate topical treatment. J Korean Ophthalmol Soc 2014;55(2):293-297

참고문헌 (Reference)

1 Bouché O, "Trichomegaly of the eyelashes following treatment with cetuximab" 16 : 1711-1712, 2005

2 Papadopoulos R, "Trichomegaly induced by erlotinib" 27 : 329-330, 2008

3 Tsubota K, "Treatment of dry eye by autologous serum application in Sjögren's syndrome" 83 : 390-395, 1999

4 Lyu J, "Transactivation of EGFR mediates insulin-stimulated ERK1/2 activation and enhanced cell migration in human corneal epithelial cells" 12 : 1403-1410, 2006

5 Ricciardi S, "Toxicity of targeted therapy in non-small-cell lung cancer management" 10 : 28-35, 2009

6 Förster CG, "Topical application of EGF for the therapy of persisting corneal erosion under cetuximab treatment" 105 : 269-273, 2008

7 Nakamura Y, "The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis" 72 : 511-517, 2001

8 Li T, "Skin toxicities associated with epidermal growth factor receptor inhibitors" 4 : 107-119, 2009

9 Xu KP, "Role of ErbB2 in corneal epithelial wound healing" 45 : 4277-4283, 2004

10 Foerster CG, "Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody)" 27 : 612-614, 2008

11 Johnson KS, "Persistent corneal epithelial defect associated with erlotinib treatment" 28 : 706-707, 2009

12 Frankfort BJ, "Periocular cutaneous toxicity and cicatricial ectropion: a potential class effect of antineoplastic agents that inhibit EGFR signaling" 23 : 496-497, 2007

13 Tullo AB, "Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials" 19 : 729-738, 2005

14 Methvin AB, "Newly recognized ocular side effects of erlotinib" 23 : 63-65, 2007

15 Modjtahedi H, "Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities" 20 : 851-855, 2009

16 Peréz-Soler R, "Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?" 23 : 5235-5246, 2005

17 Garibaldi DC, "Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab" 23 : 62-63, 2007

18 Kojima T, "Autologous serum eye drops for the treatment of dry eye diseases" 27 (27): S25-S30, 2008

19 Matsumoto Y, "Autologous serum application in the treatment of neurotrophic keratopathy" 111 : 1115-1120, 2004

20 Flynn JF, "Anti-EGFR therapy: mechanism and advances in clinical efficacy in breast cancer" 2009 : 526963-, 2009

21 Zhang G, "Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature" 26 : 858-860, 2007